Burrill & Company has held a second close of its Burrill Capital Fund IV, L.P., bringing the aggregate capital commitments to $505 million. The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.
“We are pleased that our new fund generated strong interest among investors,” says G. Steven Burrill, CEO of Burrill & Company. “This is a time of great opportunities globally for investors in the life sciences, not just in traditional sectors, but emerging areas brought about by the convergence of healthcare and information technology.” The firm held a first close of fund 4 at $313 million in December 2011.
Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm’s businesses include venture capital, private equity, merchant banking, and media. The firm was founded in 1994 and is headquartered in San Francisco, CA (www.burrillandco.com).